For high-risk adult patients
For hyperuricemic adult patients
CLL=chronic lymphocytic leukemia; SLL=small lymphocytic lymphoma.
Overall adult patient population
96% of ELITEK adult patients (n=275) achieved uric acid levels ≤2 mg/dL within 4 hours after their first dose vs 0% with allopurinol1,4
*Plasma uric acid AUC from Day 1 through Day 7 was significantly lower for ELITEK and ELITEK + allopurinol than for allopurinol alone (P<0.001).1
WARNING: HYPERSENSITIVITY REACTIONS, HEMOLYSIS, METHEMOGLOBINEMIA, AND INTERFERENCE WITH URIC ACID MEASUREMENTS
ELITEK is contraindicated in patients with a history of anaphylaxis or severe hypersensitivity to rasburicase or in patients with development of hemolytic reactions or methemoglobinemia with rasburicase. ELITEK is contraindicated in individuals deficient in glucose-6-phosphate dehydrogenase (G6PD).
Most common adverse reactions (incidence ≥20%), when used concomitantly with anticancer therapy, are vomiting, nausea, fever, peripheral edema, anxiety, headache, abdominal pain, constipation, diarrhea, hypophosphatemia, pharyngolaryngeal pain, and increased alanine aminotransferase.
USE IN SPECIFIC POPULATIONS